Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Emerging Adulthood01:27

Emerging Adulthood

638
Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
638
Introduction Cardiac Emergencies01:30

Introduction Cardiac Emergencies

299
Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
299
Gene Therapy00:59

Gene Therapy

27.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
Second Order systems II01:18

Second Order systems II

390
In an underdamped second-order system, where the damping ratio ζ is between 0 and 1, a unit-step input results in a transfer function that, when transformed using the inverse Laplace method, reveals the output response. The output exhibits a damped sinusoidal oscillation, and the difference between the input and output is termed the error signal. This error signal also demonstrates damped oscillatory behavior. Eventually, as the system reaches a steady state, the error diminishes to zero.
390
First Order Systems01:21

First Order Systems

402
First-order systems, such as RC circuits, are foundational in understanding dynamic systems due to their straightforward input-output relationship. Analyzing their responses to different input functions under zero initial conditions reveals significant insights into system behavior.
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
402
Second Order systems I01:20

Second Order systems I

575
A servo system exemplifies a second-order system, featuring a proportional controller and load elements that ensure the output position aligns with the input position. The relationship between these components is described by a second-order differential equation. Applying the Laplace transform under zero initial conditions yields the transfer function, showing how inputs are converted to outputs in the system.
By reinterpreting the system, one can derive the closed-loop transfer function, which...
575

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

JTO clinical and research reports·2026
Same author

Endomyocardial Biopsy in Suspected Immune Checkpoint Inhibitor-Myocarditis: Histologic Spectrum and Correlations With Clinical and Cardiac Magnetic Resonance Features.

Journal of the American Heart Association·2026
Same author

Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences.

Cancer communications (London, England)·2026
Same author

High-Throughput Geocoding to Assess Short-Term Air Pollution in Correlation With Mortality in a French Cancer Patient Cohort.

International journal of cancer·2026
Same author

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.

Cancer medicine·2026
Same author

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.

Oncology and therapy·2026

Related Experiment Video

Updated: Jan 21, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K

Thymic malignancies: emerging systemic therapies.

Nicolas Girard1

  • 1Institut du Thorax Curie-Montsouris, Institut Curie, Paris, France.

Current Opinion in Oncology
|August 9, 2019
PubMed
Summary
This summary is machine-generated.

Novel systemic agents show promise for advanced thymic malignancies, including phosphatidylinositol 3-kinase/mechanistic target of rapamycin kinase inhibitors and antiangiogenic agents. Further research is needed to optimize treatment sequences and patient selection for improved survival.

More Related Videos

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

7.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.0K

Related Experiment Videos

Last Updated: Jan 21, 2026

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:32

Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish

Published on: February 22, 2019

7.5K
A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

7.6K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.0K

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Thymic malignancies require multidisciplinary management.
  • Systemic therapy is crucial when local treatment is not feasible.
  • Genomic analyses reveal targetable pathways in thymomas and thymic carcinomas.

Purpose of the Study:

  • To review the role of novel systemic agents in advanced thymic malignancies.
  • To discuss challenges and future directions in the treatment of these rare cancers.

Main Methods:

  • Review of Phase II clinical trials.
  • Analysis of integrated genomic data.
  • Assessment of antitumor activity of various systemic agents.

Main Results:

  • Phosphatidylinositol 3-kinase/mechanistic target of rapamycin kinase inhibitors, cyclin dependent kinase inhibitors, and antiangiogenic agents demonstrated antitumor activity.
  • Immune checkpoint inhibitors present challenges due to autoimmune associations.
  • Phase II trials show variable efficacy in selected patient cohorts.

Conclusions:

  • Innovative agents are emerging for thymic malignancies.
  • Understanding real-world treatment sequences is essential for optimizing efficacy.
  • Individualized treatment strategies are needed to improve patient survival.